NeuroOne Medical Technologies公司已向美国证券交易委员会（SEC）提交了一份更新的招股说明书补充文件，为其计划进行的“按市价发行”（ATM）股票增发计划铺平道路。此次增发拟募集资金最高可达1340万美元。
ATM发行机制允许上市公司在特定时期内，根据市场情况持续或间歇地出售新发行股票，从而更为灵活地筹集资金。公司此次提交更新文件，旨在为后续在公开市场进行股票发售提供必要的法律与监管依据。
NeuroOne Medical Technologies公司已向美国证券交易委员会（SEC）提交了一份更新的招股说明书补充文件，为其计划进行的“按市价发行”（ATM）股票增发计划铺平道路。此次增发拟募集资金最高可达1340万美元。
ATM发行机制允许上市公司在特定时期内，根据市场情况持续或间歇地出售新发行股票，从而更为灵活地筹集资金。公司此次提交更新文件，旨在为后续在公开市场进行股票发售提供必要的法律与监管依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.